AI-generated summary
The authors report a randomized trial in 25 transgender men comparing combined 595-nm pulsed dye laser and intralesional triamcinolone with triamcinolone alone for postmastectomy scars, with each participant receiving both treatments on opposite sides of the chest. The combined treatment showed greater improvement in scar scores and melanin index, with higher participant satisfaction and no serious adverse events reported. Limitations include the small sample size.
- Participants
- 25
- Who or what was studied
- Transgender men with postmastectomy hypertrophic scars or keloids
- Wavelengths
- 595 nm
- Limits stated in the abstract
- The abstract describes a small sample of 25 participants and does not state a long-term follow-up beyond 6 months.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
Top surgery masculinizes the chest appearance for transgender men (TM); however, some individuals may experience hypertrophic scars (HTS) or keloids following the surgery.
Objectives
This study aimed to evaluate the efficacy of combined 595-nm pulsed dye laser (PDL) and intralesional triamcinolone acetonide injection (IL TAC) compared to IL TAC monotherapy for treating HTS and keloids.
Methods
Twenty-five TM with 35 pairs of bilateral symmetric postmastectomy HTS or keloids were randomly allocated to receive the combined PDL and IL TAC on the scar(s) on one side of the chest and IL TAC monotherapy on the contralateral scar(s) in four monthly treatment sessions. Clinical improvement was evaluated using the Vancouver Scar Scale (VSS). Melanin index, hemoglobin index, and scar roughness were determined before each treatment session and at 1, 3, and 6 months after the last treatment. Participant-rated satisfaction and adverse events were documented.
Results
After two treatment sessions, scars treated with combined PDL and IL TAC demonstrated significantly greater improvements in the VSS (p = 0.012) and melanin index (p = 0.004) compared to those treated with IL TAC alone. The superior outcomes of the combined therapy persisted for 3 and 6 months after the end of treatment sessions for the VSS (p = 0.001) and melanin index (p = 0.048), respectively. Participants reported higher satisfaction for combined PDL and IL TAC than IL TAC monotherapy (p = 0.005). No serious or permanent adverse event was reported.
Conclusion
The addition of 595-nm PDL to IL TAC may provide more favorable outcomes for treating postmastectomy HTS and keloids among TM.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Randomized controlled trial, Melanin, Adverse event. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.